drugset / Trial / NCT04148391
NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)
Phase 2
Active not recruiting
99 enrolled
Aptinyx
CogState Ltd. · collabWorldwide Clinical Trials · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia
Timeline
- Start
- 2019-11-14
- Primary completion
- 2022-12-30
- Completion
- 2022-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NEVADISTINEL | Small molecule | 30 mg | Oral |